NCT03822559View on ClinicalTrials.gov

A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

219

Participants

Timeline

Start Date

January 20, 2019

Primary Completion Date

April 4, 2023

Study Completion Date

April 4, 2023

Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
DRUG

A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL

One drop a time, once daily administration of DE-111A eye drops in the affected eye(s) at 8:00 am (±1h) for 3 months.

DRUG

A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost in 1mL

One drop a time, once daily administration of preservative-free 0.0015% tafluprost eye drops in the affected eye(s) at 8:00 (±1h) for 3 months.

Trial Locations (2)

Unknown

Aier Eye Hospital Group Co., Ltd Changsha Aier Eye Hospital, Changsha

Eye & Ent Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Santen Pharmaceutical Co., Ltd.

INDUSTRY

NCT03822559 - A Study of DE-111A on the Treatment of Open Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter